Incyte presents data from positive Phase III study in atopic dermatitis

6 April 2020

Incyte (Nasdaq: INCY) has presented positive Phase III data for ruxolitinib cream in atopic dermatitis at a virtual symposium, called Revolutionizing Atopic Dermatitis.

Data from the Phase III TRuE-AD program, which includes the TRuE-AD1 and TRuE-AD2 studies, show that both studies met the primary endpoint of skin clearance.

The trial program is evaluating ruxolitinib for mild-to-moderate forms of atopic dermatitis, a condition which affects at least 11 million people in the USA. Top-line results from studies were released earlier in 2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK